fda compounded semaglutide news US proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs Hims & Hers stock falls

The OASIS 4 trial evaluated the safety and effectiveness of once-daily semaglutide25 mgin obese and overweight patients without T2DM

Issue 42 of The Altascientist explores GLP-1 receptor agonist drug development, covering preclinical models, bioanalytical assays, clinical study design, and manufacturing

Substancj czynn zawart w leku jest semaglutyd, ktry zalicza si do grupy agonistw receptora GLP-1

Highly sensitive GLP-1 formulations demand a packaging that preserves stability, ensures precise dosing, and performs seamlessly with delivery devices

Discover its side effects, cost, and effectiveness for weight loss.

GLP-1 is a hormone produced in the intestines that plays a crucial role in regulating blood sugar levels